ClinicalTrials.gg
CompletedNCT01616654Updated Sep 20, 2021Results posted

Dose Range Study of CD5789 in Acne Vulgaris

A Phase 2 interventional study of CD5789 25 µg/g cream and CD5789 50 µg/g cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 24 sites in United States. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2021-09-20.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Enrollment
8th of 12
304 · median 507
Started
2012
the only one that year
Phase 2
Only one
of the 12
Registered
1st of 12
by date
Lead sponsor
9 of 12
Galderma R&D

Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 8th largest by enrollment, is the only one that started in 2012, is the only one in phase 2, and was the 1st registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant, 12 to 35 years old with the following characteristics:
  • Facial acne severity grade of the following:

    • Stratum 1: IGA score of 3 or 4
    • Stratum 2: IGA score of 4
    • Stratum 3: IGA score of 3 or 4
  • A minimum of 30 non-inflammatory lesions and fulfills the criteria of one of the following strata:

    • Stratum 1: A minimum of 20 but not more than 40 inflammatory lesions, and a maximum of one nodule on the face.
    • Stratum 2: More than 40 inflammatory lesions, and up to four nodules on the face.
    • Stratum 3: Participants of Japanese origin with at least 20 inflammatory lesions and up to four nodules on the face.

      • Note: Participants of Japanese origin will not be included in Stratum 1 or Stratum 2. Japanese origin is defined as all four grandparents were born in Japan.

Exclusion criteria

Exclusion Criteria:

  • The presence of severe forms of acne (acne conglobata, acne fulminans) or secondary acne form (chloracne, drug-induced acne, etc.)
  • Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results and/or put the participant at significant risk (according to the Investigator's judgment) if the participant participates in the clinical trial.
  • Known or suspected allergies or sensitivities to any components of any of the study drugs.
  • Current participation in any other clinical trial of a drug or device OR past participation within the 30 days prior to the Baseline visit.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    CD5789 25 mcg/g Cream

    Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.

    Drug: CD5789 25 µg/g cream

  • Experimental
    CD5789 50 mcg/g Cream

    Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.

    Drug: CD5789 50 µg/g cream

  • Active comparator
    CD5789 100 mcg/g Cream

    Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.

    Drug: CD5789 100 µg/g cream

  • Placebo comparator
    Tazarotene 0.1% Gel

    Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.

    Drug: Tazarotene 0.1% gel

  • Experimental
    Vehicle Cream

    Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.

    Drug: Vehicle cream

Interventions

  • DrugCD5789 25 µg/g cream

    Drug page: Trifarotene

    CD5789 25 µg/g cream applied once daily

  • DrugCD5789 50 µg/g cream

    Drug page: Trifarotene

    CD5789 50 µg/g cream applied once daily

  • DrugCD5789 100 µg/g cream

    Drug page: Trifarotene

    CD5789 100 µg/g cream applied once daily

  • DrugTazarotene 0.1% gel

    Tazarotene 0.1% gel applied once daily

  • DrugVehicle cream

    Vehicle cream applied once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Success Rate 1 (SR1)

    Success Rate 1 was defined as percentage of participants who achieved at least a two-point reduction in the Investigator Global Assessment (IGA) scale from baseline at week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by last observation carried forward (LOCF).

    Time frame: From Baseline at Week 12

  2. Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)

    The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.

    Time frame: Baseline, Week 12

  3. Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)

    The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Participants With Success Rate 2 (SR2)

    Success Rate 2 (SR2) was defined as the percentage of participants rated "Clear" (Grade 0) or "Almost clear" (Grade 1) with at least a two-point reduction on the IGA scale from Baseline to Week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by LOCF.

    Time frame: From Baseline to Week 12

  2. Absolute Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)

    The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF.

    Time frame: Baseline, Week 12

  3. Percentage Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)

    The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF. Percent changes in lesion counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100.

    Time frame: Baseline, Week 12

07

Results

Posted Sep 20, 2021

Participant flow

The study was conducted in United States. A total of 422 participants were screened between 20 June 2012 to 01 May 2013. Of which, 118 were screen failures. Screen failures were mainly due to inclusion criteria not met. A total of 304 participants were randomized in the study.

Participant flow — Overall Study
MilestoneCD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelVehicle Cream
Started6161606161
Completed5653505349
Not completed5810812
Withdrew: Lack of efficacy10001
Withdrew: Adverse event01210
Withdrew: Withdrawal by subject22315
Withdrew: Protocol violation05244
Withdrew: Lost to follow-up10321
Withdrew: Pregnancy10001

Outcome measures

PrimaryPercentage of Participants With Success Rate 1 (SR1)

Success Rate 1 was defined as percentage of participants who achieved at least a two-point reduction in the Investigator Global Assessment (IGA) scale from baseline at week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by last observation carried forward (LOCF).

Time frame:
From Baseline at Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Success Rate 1 (SR1)
percentage of participantsCD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelCD5789 Vehicle Cream
Percentage of Participants With Success Rate 1 (SR1)29.5132.7926.6732.7916.39
Statistical analysis
  • CD5789 25 mcg/g Cream vs CD5789 Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.096 · Percentage difference: 13.115 · 95% CI -3.266 to 29.495
  • CD5789 50 mcg/g Cream vs CD5789 Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.040 · Percentage difference: 16.393 · 95% CI -0.249 to 33.036
  • CD5789 100 mcg/g Cream vs CD5789 Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.184 · Percentage difference: 10.273 · 95% CI -5.923 to 26.470
  • Tazarotene 0.1% Gel vs CD5789 Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.041 · Percentage difference: 16.393 · 95% CI -0.249 to 33.036
PrimaryAbsolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)

The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)
lesion countCD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelVehicle Cream
Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)-53.61 ± 8.314-54.75 ± 8.261-54.99 ± 8.296-59.84 ± 8.301-46.87 ± 7.934
Statistical analysis
  • CD5789 25 mcg/g Cream vs Vehicle Cream · ANCOVA · p = 0.108 · Percentage difference: -6.74 · 95% CI -14.96 to 1.48
  • CD5789 50 mcg/g Cream vs Vehicle Cream · ANCOVA · p = 0.060 · Percentage difference: -7.88 · 95% CI -16.11 to 0.34
  • CD5789 100 mcg/g Cream vs Vehicle Cream · ANCOVA · p = 0.054 · Percentage difference: -8.11 · 95% CI -16.35 to 0.13
  • Tazarotene 0.1% Gel vs Vehicle Cream · ANCOVA · p = 0.002 · Percentage difference: -12.97 · 95% CI -21.18 to -4.76
PrimaryPercentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)

The lesion counts were performed by the Investigator. Total lesion counts was the sum of inflammatory, non-inflammatory lesions and nodules. All missing values were imputed by LOCF.

Time frame:
Baseline, Week 12
Reported as:
Mean · percentage change
Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)
percentage changeCD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelCD5789 Vehicle Cream
Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)-47.59 ± 28.474-49.87 ± 24.731-50.72 ± 24.885-55.07 ± 26.295-40.48 ± 28.968
Statistical analysis
  • CD5789 25 mcg/g Cream vs CD5789 Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.067
  • CD5789 50 mcg/g Cream vs CD5789 Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.054
  • CD5789 100 mcg/g Cream vs CD5789 Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.038
  • Tazarotene 0.1% Gel vs CD5789 Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.003
SecondaryPercentage of Participants With Success Rate 2 (SR2)

Success Rate 2 (SR2) was defined as the percentage of participants rated "Clear" (Grade 0) or "Almost clear" (Grade 1) with at least a two-point reduction on the IGA scale from Baseline to Week 12. Evaluation of acne was performed by the investigator based on the following 5 point scale: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe, higher score indicated higher severity. All missing values were imputed by LOCF.

Time frame:
From Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Success Rate 2 (SR2)
percentage of participantsCD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelVehicle Cream
Percentage of Participants With Success Rate 2 (SR2)13.1114.7516.6721.318.20
SecondaryAbsolute Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)

The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF.

Time frame:
Baseline, Week 12
Reported as:
Mean · lesion count
Absolute Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)
lesion countCD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelCD5789 Vehicle Cream
Inflammatory Lesions-19.67 ± 14.874-21.11 ± 13.268-19.32 ± 11.566-21.03 ± 13.890-17.74 ± 15.073
Non-inflammatory Lesions-24.30 ± 21.633-18.69 ± 12.895-23.70 ± 18.390-28.26 ± 26.346-17.70 ± 17.745
SecondaryPercentage Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)

The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 1 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). All missing values were imputed by LOCF. Percent changes in lesion counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100.

Time frame:
Baseline, Week 12
Reported as:
Mean · percentage change
Percentage Change From Baseline in Inflammatory and Non-inflammatory Lesion Count up to Week 12 Using Last Observation Carried Forward (LOCF)
percentage changeCD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelCD5789 Vehicle Cream
Inflammatory lesion count-49.16 ± 35.711-53.14 ± 30.187-51.93 ± 27.255-53.09 ± 29.484-41.70 ± 35.898
Non-inflammatory lesion count-46.34 ± 30.888-45.26 ± 29.331-49.57 ± 29.786-55.88 ± 28.913-38.20 ± 30.368

Adverse events

Collected over Adverse events (AEs) that occurred on or after the first dose of study medication through Week 14 Follow-up visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD5789 25 mcg/g Cream0/61 (0%)1/61 (1.6%)15/61 (24.6%)
CD5789 50 mcg/g Cream0/61 (0%)1/61 (1.6%)17/61 (27.9%)
CD5789 100 mcg/g Cream0/60 (0%)0/60 (0%)23/60 (38.3%)
Tazarotene 0.1% Gel0/61 (0%)0/61 (0%)24/61 (39.3%)
CD5789 Vehicle Cream0/61 (0%)1/61 (1.6%)18/61 (29.5%)
Most frequent serious events
Most frequent serious events
EventCD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelCD5789 Vehicle Cream
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/610/610/600/611/61
DepressionPsychiatric disorders0/611/610/600/610/61
Most frequent other events
Showing 10 of 73
Most frequent other events
EventCD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelCD5789 Vehicle Cream
Skin irritationSkin and subcutaneous tissue disorders0/610/616/605/610/61
Upper respiratory tract infectionInfections and infestations2/613/614/601/616/61
NasopharyngitisInfections and infestations4/611/615/605/611/61
HeadacheNervous system disorders2/612/611/601/613/61
InfluenzaInfections and infestations1/610/612/600/610/61
PruritusSkin and subcutaneous tissue disorders0/610/612/601/610/61
Skin burning sensationSkin and subcutaneous tissue disorders0/611/610/602/610/61
Pityriasis albaSkin and subcutaneous tissue disorders0/610/610/602/610/61
ExcoriationInjury, poisoning and procedural complications0/610/610/602/610/61
Electrocardiogram abnormalInvestigations0/610/610/600/612/61

Baseline characteristics

Analysis was performed on Intent to treat (ITT) population that included all participants who were randomized and to whom study drug was dispensed.

Age, Continuous
Age, Continuous(years)CD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelVehicle CreamTotal
Mean18.1 ± 5.2618.2 ± 4.7618.3 ± 5.5918.3 ± 4.8318.3 ± 4.8418.2 ± 5.03
Sex: Female, Male
Sex: Female, Male(Participants)CD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelVehicle CreamTotal
Female15812171365
Male4653484448239
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD5789 25 mcg/g CreamCD5789 50 mcg/g CreamCD5789 100 mcg/g CreamTazarotene 0.1% GelVehicle CreamTotal
American Indian or Alaska Native000202
Asian020013
Native Hawaiian or Other Pacific Islander000000
Black or African American978121349
White5251524747249
More than one race000000
Unknown or Not Reported010001
08

Study locations

24 sites
  • Total Skin and Beauty Dermatology Center, PC
    Birmingham, Alabama 35205, United States
  • Parexel Early Phase
    Glendale, California 91206, United States
  • Odyssey Medispa
    Marina Del Rey, California 90292, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • FXM Research Corp Miami
    Miami, Florida 33175, United States
  • FMX Research Miramar
    Miramar, Florida 33027, United States
  • Meda Phase, Inc
    Newnan, Georgia 30263, United States
  • Deaconess Clinic, Inc.
    Evansville, Indiana 47713, United States
  • Dermatology Specialists PC
    Louisville, Kentucky 40202, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Somerset Skin Centre
    Troy, Michigan 48084, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Academic Dermatology Associates
    Albuquerque, New Mexico 87106, United States
  • Zoe Drealos, MD
    High Point, North Carolina 27262, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Central Sooner Research
    Norman, Oklahoma 73069, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Palmetto Clinical Trial Services, LLC
    Greenville, South Carolina 29607, United States
  • Arlington Center for Dermatology
    Arlington, Texas 76011, United States
  • Suzanne Bruce and Associates P.A. The Center for Skin Research
    Houston, Texas 77056, United States
  • Stephen Miller MD
    San Antonio, Texas 78229, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Dermatology Research Center
    Salt Lake City, Utah 84124, United States
  • The Education & Research Foundation, Inc.
    Lynchburg, Virginia 24501, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Jul 2013, 13 months.

Results were first posted in Sep 2021, 8 years 1 month after primary completion. A results delay was requested in Jan 2014.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 13 months is above that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2012
First posted
Jun 12, 2012
StartActual
Jun 20, 2012
Primary completionActual
Jul 24, 2013
CompletionActual
Jun 12, 2014
Results delay requested
Jan 14, 2014
Results first posted
Sep 20, 2021
Last update
Sep 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01616654
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 12, 2012
Start date
Jun 20, 2012
Primary completion
Jul 24, 2013
Completion
Jun 12, 2014
Results posted
Sep 20, 2021
Last update
Sep 20, 2021

Study contacts

Michael Graeber, M.D.
study director · Galderma R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion